drugset / Trial / NCT04547062

Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML)

NCT04547062

Phase 1 Completed 12 enrolled Nantes University Hospital
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a phase 1 dose escalation study testing the addition of an anti-IL6 (tocilizumab) to standard induction chemotherapy for high-risk AML.

Timeline

Start
2020-12-29
Primary completion
2023-04-04
Completion
2023-04-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Tocilizumab Monoclonal antibody 4 mg/kg Intravenous
Subject Tocilizumab Monoclonal antibody 6 mg/kg Intravenous
Subject Tocilizumab Monoclonal antibody 8 mg/kg Intravenous